Yuanbao (YB) Q4 2025 earnings review
Top-Line Momentum Continues, But S&M Spend Crushes the Efficiency Narrative
Yuanbao closed FY25 with robust top-line growth, as Q4 revenues grew 32.2% YoY, driven by a massive 34.5% increase in new policies. However, the bottom-line narrative is deteriorating. Net Income growth decelerated sharply to 15.4% YoY (down from 51.3% in Q3), compressing the net margin to 28.7%. The primary culprit is a 47.7% YoY explosion in Selling & Marketing expenses. This aggressively contradicts management's ongoing narrative of AI-driven operational efficiency. Combined with a massive spike in withholding tax, Yuanbao is proving it can sell insurance at scale, but customer acquisition costs are moving in the wrong direction.
🐂 Bull Case
Volume growth is exceptional. The platform processed 7.9 million new policies in Q4 alone (+34.5% YoY), proving the company's ability to consistently acquire users and penetrate the inclusive health insurance market.
B2B System Services revenue grew 31.1% YoY to RMB 774.1 million. Supplying precise analytics and marketing services to carrier partners continues to be a reliable and highly scalable engine.
🐻 Bear Case
The 47.7% surge in Selling & Marketing expenses vastly outpaced revenue growth (32.2%). If Yuanbao must buy its growth at an accelerating cost, the company's AI-efficiency moat is weaker than advertised.
Income tax expense skyrocketed 734.9% YoY to RMB 75.4 million due to withholding income tax accruals. If this reflects a structural change rather than a one-time adjustment, future earnings power will be permanently impaired.
⚖️ Verdict: ⚪
Neutral. The volume and revenue stories are excellent, and a RMB 4.0 billion cash pile provides a deep safety net. However, the sudden, aggressive deterioration in marketing efficiency and a massive tax hit prevent a bullish rating until the unit economics stabilize.
Key Themes
Contradiction: AI Efficiency vs. Exploding S&M Costs
Management continuously promotes its proprietary 'full consumer service cycle engine' as the key to superior operational efficiency. Yet, Q4 numbers show Selling & Marketing expenses accelerating dramatically to 47.7% YoY growth, costing RMB 552.3M. This represents a severe break in trend from H1 2025, where S&M grew around 14-15%. Either competition for traffic has intensified, or the AI's ability to optimize customer acquisition costs has plateaued.
Deepening LLM Integration and Agent Deployment
Yuanbao expanded its AI matrix to over 4,900 models covering 5,700 labels. More importantly, they transitioned from backend R&D usage to scaled front-line deployment of 'Insurance Agents.' These multimodal AI agents are now actively handling pre-sales, product explanations, and claims document extraction, indicating a technological maturation that could structurally lower Ops & Support costs (which did decline 13.7% YoY in Q4).
Rapid Expansion of Product Offerings
The company's strategy of 'inclusive insurance' continues to yield results. Building on the Q3 launch of short-term critical illness insurance, Yuanbao added a 'Zero-Deductible' Million-RMB Medical Insurance Plan and quickly integrated the new national 'Commercial Insurance Innovative Drug Catalog'. This rapid product iteration allows them to upsell effectively and capitalize on shifting national health policies.
System Services Segment Resilience
System Services remains the largest revenue contributor, generating RMB 774.1 million (+31.1% YoY). Providing analytics and precision marketing to insurers is highly synergistic with their core distribution business. As long as insurance carriers demand better targeting, Yuanbao’s data advantage makes this a durable growth engine.
Withholding Tax Shock
Net income margin compression wasn't just driven by marketing. Income tax expenses spiked a staggering 734.9% YoY to RMB 75.4 million. Management attributed this to 'the accrual of withholding income tax in the fourth quarter.' This needs immediate clarification: if Yuanbao is now subject to structurally higher tax rates, analyst EPS estimates for FY26 must be revised downward.
Capital Allocation Void Amid Cash Hoarding
Yuanbao ended FY25 with RMB 4.04 billion in cash, time deposits, and short-term investments (up 73% YoY). Despite being explicitly asked about buybacks and dividends by analysts in the Q3 call, management has announced zero capital return initiatives. Hoarding cash while the stock presumably trades at a discount raises questions about capital efficiency and management's alignment with minority shareholders.
Macro Tax Regulation Impact Unclear
In Q3, analysts raised concerns about a new macro tax regulation capping ad spend deductions at roughly 15%. While management brushed it off previously, the acceleration in S&M expenses in Q4, coupled with higher tax lines, suggests that the macro environment for customer acquisition and associated tax penalties in China may be worsening.
Other KPIs
Accelerating. Up 39.1% YoY. While this is a high growth rate, it is well-justified by the company's aggressive pivot toward LLMs and AI Agents. Given the reduction in Ops & Support expenses, the R&D investment appears to be yielding tangible operational automation.
Stable and compounding. The balance sheet is impregnable, having grown 72.9% YoY and 7.7% QoQ. The business generated RMB 1.49 billion in operating cash flow for the year. This provides immense flexibility for M&A, R&D scaling, or—if management decides to implement it—shareholder returns.
Decelerating. Dropped 22.5% YoY. Management noted this was due to the absence of one-off project bonuses recorded in Q4 2024. This helped partially offset the severe margin drag from the S&M and Tax spikes.
Key Questions
S&M Efficiency Disconnect
Selling and Marketing expenses grew 47.7% YoY in Q4, vastly outpacing revenue growth. Does this indicate a structural increase in customer acquisition costs, increased competitive bidding for traffic, or diminishing returns on your AI marketing algorithms?
Withholding Tax Run-Rate
Income tax expenses spiked over 700% due to withholding tax accruals. Is this RMB 75 million quarterly tax expense the new normal run-rate going forward, or was this a one-time true-up for the fiscal year?
Capital Return Policy
With cash reserves now surpassing RMB 4 billion and operating cash flow highly positive, what are the specific hurdles preventing the board from authorizing a share repurchase program or issuing a special dividend?
Ad Spend Tax Cap Impact
Given the recent 15% cap on ad spend deductions mentioned in prior quarters, to what extent did this macro policy contribute to the margin compression and S&M/Tax dynamic we saw in Q4?